About Us – Verdant

Verdant was founded by economists and policy experts who have worked together for over a decade at the center of U.S. drug pricing reform.

At Memorial Sloan Kettering’s Drug Pricing Lab, the team built foundational research on Medicare Part B and Part D reform, bringing together knowledge from careers in industry, financial markets, academia, and government. Founder Anna Kaltenboeck went on to lead Senate Finance Committee work on the Medicare Drug Price Negotiation Program. Now, Verdant brings that rigor to evaluate how reimbursement systems shape markets, innovation, and patient access.

The Team

Anna Kaltenboeck

President

Anna Kaltenboeck is the founder and President of Verdant Research. Prior to founding Verdant, she was Senior Health Advisor on the Senate Committee on Finance, where she led on drug pricing issues including Medicare negotiation. In her previous role as Program Director for the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center, she studied how reimbursement policies shape the market for prescription drugs. Her work is informed by the first decade of her career as a consultant for life sciences and pharmaceutical companies.
She advises foundations, legislators and agencies, and private sector organizations on drug payment reforms and competition policy and acts as an expert witness on legal matters related to prescription drug payment and distribution.
Tufts University (BA, MA Economics); Yale School of Management (MBA)

Jennifer C. Chen

Program Director

Jennifer Chen leads Verdant’s research and advisory engagements focused on prescription drug reimbursement and market analysis. Her previous roles includes drug pricing and reimbursement consulting and analytics, market access and medical affairs for blood-based cancer screening tests, and managing the day-to-day operations of the Drug Pricing Lab within the Center for Health Policy and Outcomes, and the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center.
Jennifer brings experience across policy analysis, health services research, and pharmaceutical market strategy.
Boston University (MPH); University of California, Riverside (BS)

Lead with Evidence

Partner with Verdant for rigorous, objective economic analysis.